Drug Profile
Research programme: antibacterial therapeutics - BARDA/GlaxoSmithKline
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biomedical Advanced Research and Development Authority; GlaxoSmithKline
- Developer Biomedical Advanced Research and Development Authority; GSK
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 22 May 2013 GlaxoSmithKline receives funding from the US Department of Health and Human Services for development of Antibacterial therapeutics
- 22 May 2013 Preclinical trials in Bacterial infections in USA (unspecified route)